来自MSC的外体作为骨关节炎治疗中的药物系统
Shuzhan Wen1, Xin Huang1, Jingchun Ma1
1Department of Orthopedics, Huashan Hospital, Fudan University, Shanghai, China.
Frontiers in bioengineering and biotechnology
|April 5, 2024
概括
介质干细胞衍生外体 (MSC-Exos) 为骨关节炎 (OA) 细胞治疗提供了一个有前途的替代方案. 这些微小的囊泡提供治疗分子,调节免疫力并促进软骨再生,以有效治疗OA.
科学领域:
- 生物医学工程 生物医学工程
- 再生医学是一种再生医学.
- 整形外科 整形外科 整形外科
背景情况:
- 骨关节炎 (OA) 是一种常见的退行性关节疾病,其特征是不可逆转的软骨损伤.
- 介酶干细胞 (MSCs) 显示了OA的治疗潜力,但直接注射面临成本和道德挑战.
- 来自MSC的外体 (MSC-Exos) 是MSC治疗效果的关键媒介,携带生物活性物质.
研究的目的:
- 审查MSC-Exos在骨关节炎治疗中的治疗机制.
- 总结目前关于MSC-Exo制备方法的研究.
- 探索MSC-Exos作为OA药物输送系统的应用.
主要方法:
- 对MSC-Exos治疗骨关节炎的研究进行文献综述.
- 对MSC-Exo成分和生物功能的分析.
- 评估MSC-Exo制备技术和药物输送应用.
主要成果:
- MSC-Exos含有多种生物活性分子 (核酸,蛋白质,脂质,微RNA).
- MSC-Exos通过调节免疫力,抑制细胞亡,促进OA的再生来表现出治疗潜力.
- MSC-Exos作为有效的向性传递系统用于OA治疗.
结论:
- MSC-Exos代表了一种可行的无细胞治疗策略,用于骨关节炎.
- 对MSC-Exo制备和药物输送的进一步研究对于临床转化至关重要.
- MSC-Exos对促进骨关节炎再生医学的发展具有重大前景.
更多相关视频
相关概念视频
Mesenchymal Stem Cells
4.7K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.7K
Overview of Exosomes
2.7K
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
2.7K


